Explanipedia

Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases Open

S. Benhmida, Roger Sun, Elisabeta Gherga, Y. Hammoud, Jorge Rouvier , et al. · 2020

The present SCH-RT regimen seems effective, well-tolerated and could represent an alternative to palliative strategies for pts deemed unfit for standard exclusive RT.

Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation Open

A. Clément-Zhao, Marie‐Laure Tanguy, Paul Cottu, Brigitte De La Lande, P. Bontemps , et al. · 2019

Concurrent B and locoregional RT are associated with acceptable 5-year toxicity in patients with non-metastatic breast cancer. No grade ≥3 toxicity was observed.

A sore throat Open

Alexandre Debelmas, Sophie Lanciaux, P. Bontemps, Roman Hossein Khonsari · 2019

OC-0594 Acute toxicity results after breast-conserving therapy in “boost vs no boost (BONBIS)” DCIS trial Open

C. Bourgier, D M Cowen, C. Lemanski, Florence Castan, S. Rivera , et al. · 2019

EP-1335: Efficacy and safety of hypofractionated loco-regional radiotherapy for breast cancer patients Open

Matthieu Caubet, P. Bontemps, Amélie Anota, F. Boulbair, Y. Hammoud , et al. · 2018

Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer Open

V. Pernin, Lisa Belin, P. Cottu, P. Bontemps, C. Lemanski , et al. · 2015

The largest series of this association.

P. Bontemps YOU? Author Swipe